900 related articles for article (PubMed ID: 26202766)
1. Adoptive T-cell therapy for cancer: The era of engineered T cells.
Bonini C; Mondino A
Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
[TBL] [Abstract][Full Text] [Related]
2. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
3. CAR T cell immunotherapy for human cancer.
June CH; O'Connor RS; Kawalekar OU; Ghassemi S; Milone MC
Science; 2018 Mar; 359(6382):1361-1365. PubMed ID: 29567707
[TBL] [Abstract][Full Text] [Related]
4. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Rath JA; Arber C
Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
[TBL] [Abstract][Full Text] [Related]
5. [T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases].
Vdovin AS; Bykova NA; Efimov GA
Mol Biol (Mosk); 2017; 51(6):1008-1023. PubMed ID: 29271964
[TBL] [Abstract][Full Text] [Related]
6. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
7. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
8. Antigen choice in adoptive T-cell therapy of cancer.
Offringa R
Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
[TBL] [Abstract][Full Text] [Related]
9. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Yang QY; Yang JD; Wang YS
Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
[TBL] [Abstract][Full Text] [Related]
10. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
11. Preclinical development of T cell receptor gene therapy.
Bendle GM; Haanen JB; Schumacher TN
Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
[TBL] [Abstract][Full Text] [Related]
12. Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.
Chicaybam L; Bonamino MH
Int Rev Immunol; 2014 Oct; 33(5):402-16. PubMed ID: 24911925
[TBL] [Abstract][Full Text] [Related]
13. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
14. Redirected T cells in cancer therapy.
Sangiolo D
Expert Opin Biol Ther; 2015; 15(12):1667-70. PubMed ID: 26515608
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
Stauss HJ; Morris EC
Gene Ther; 2013 Nov; 20(11):1029-32. PubMed ID: 23804078
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
Luo C; Wei J; Han W
Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
[TBL] [Abstract][Full Text] [Related]
18. Adoptive Cellular Therapy (ACT) for Cancer Treatment.
Yang F; Jin H; Wang J; Sun Q; Yan C; Wei F; Ren X
Adv Exp Med Biol; 2016; 909():169-239. PubMed ID: 27240459
[TBL] [Abstract][Full Text] [Related]
19. Current status of genetic modification of T cells for cancer treatment.
Dotti G; Heslop HE
Cytotherapy; 2005; 7(3):262-72. PubMed ID: 16081353
[TBL] [Abstract][Full Text] [Related]
20. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.
Hardaway JC; Prince E; Arepally A; Katz SC
J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783
[No Abstract] [Full Text] [Related]
[Next] [New Search]
